Energy News
CIVIL NUCLEAR
Framatome backs Global Morpho Pharma's high-capacity Lutetium-177 separation process
Framatome Healthcare is a key player in the radioisotopes supply chain used in radiopharmaceuticals for both diagnostic imaging and therapeutic purposes.
Reuters Events SMR and Advanced Reactor 2025
Framatome backs Global Morpho Pharma's high-capacity Lutetium-177 separation process
by Staff Writers
Paris, France (SPX) Dec 07, 2023

In a significant stride towards enhancing cancer treatment technologies, Framatome has announced a collaboration with Global Morpho Pharma to develop a high-capacity technology for the purification of non-carrier-added (n.c.a.) Lutetium-177 (Lu-177), a crucial medical radioisotope. This partnership is poised to meet the surging demand for Lu-177 and foster advancements in cancer therapies.

Global Morpho Pharma has innovated a patented technology that remarkably separates Lu-177 from Ytterbium-176 (Yb-176) targets, offering up to 50 times greater capacity than current technologies. Under this new agreement, Framatome will extend its laboratory expertise and services to scale this pilot technology to industrial levels at its Technical Center in Erlangen, Germany.

Francois Gauche, Director of Framatome Healthcare, expressed pride in this collaboration. "Global Morpho Pharma's choice of Framatome to industrialize their groundbreaking technology is a testament to our team's competence and flexibility. This initiative extends our services beyond power-generating nuclear stations, marking a significant contribution to nuclear medicine technology," he stated.

The demand for n.c.a. Lu-177 is projected to grow 15-fold by 2030, with an expected reach to 300,000 patients treated. This increasing demand necessitates innovations across the manufacturing chain, and Global Morpho Pharma's technology is a key player in meeting this need. The technology promises a substantial leap in target processing capacity, ensuring a stable supply of n.c.a Lu-177.

Francois Zimmermann, CEO of Global Morpho Pharma, looks forward to the partnership. "Validating our high mass processing technology at an industrial scale with Framatome's support is a significant step. This technology, coupled with our KaLupso solution for local Lu-177 processing, will streamline the value chain in a market where diversification and efficiency are crucial," he commented.

This partnership cements Global Morpho Pharma's position as a leader in medical radioisotope production technology and underscores Framatome Healthcare's commitment to pioneering cancer treatments using nuclear technologies.

Lu-177, a beta-emitting radioisotope, is instrumental in targeted radionuclide therapy, particularly in treating prostate cancer. It also shows promise in other cancer treatment developments. Framatome's proprietary isotope production technology marked a milestone in June 2022 by facilitating the first large-scale commercial production of n.c.a. Lu-177 in a power reactor.

Related Links
Framatome
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com

Subscribe Free To Our Daily Newsletters
Tweet

RELATED CONTENT
The following news reports may link to other Space Media Network websites.
CIVIL NUCLEAR
China launches world's first fourth-generation nuclear reactor
Beijing (AFP) Dec 6, 2023
China began commercial operations of the world's first next-generation, gas-cooled nuclear reactor power plant, state media reported Wednesday. The Shidao Bay plant in eastern Shandong province is powered by two high-temperature reactors cooled by gas rather than pressurised water, according to state news agency Xinhua, making it more efficient and cost-effective. Conventional reactors produce electricity from nuclear energy. However, these advanced models - known as small modular reactors, or ... read more

CIVIL NUCLEAR
Nigerians look to biofuel as cost of cooking gas soars

Chinese company gives leftover hotpot oil second life as jet fuel

Cheap and efficient ethanol catalyst from laser-melted nanoparticles

UK permits 'world-first' flight powered by sustainable fuels

CIVIL NUCLEAR
Harnessing solar power for atmospheric water harvesting

China's Quest for Space-Based Solar Power: A Clean Energy Revolution

Solar-Powered Economic Growth: Qihe County's Commitment to Sustainable Energy

Innovative supercrystal material ushers new era in solar energy efficiency

CIVIL NUCLEAR
UK unveils massive news windfarm investment by UAE, German firms

Wind and solar projects can profit from bitcoin mining

Winds of change? Bid to revive England's onshore sector

Drones to transport personnel and materials to offshore wind farms

CIVIL NUCLEAR
'Unabated': a word to split the world at COP28

'Climate conscious' banks lend more to polluters; Denmark wants 90% cut by 2040

Are COPs useful? A defence from five participants

COP28 draft agreement includes option to do nothing on fossil fuels

CIVIL NUCLEAR
Cost-effective electrocatalysts for cleaner hydrogen fuel production

Japanese experimental nuclear fusion reactor inaugurated

New study shows how universities are critical to emerging fusion industry

Glencore eyes options on battery recycling project

CIVIL NUCLEAR
COP28 host UAE choking from its own 'toxic' air pollution: HRW

To greenwash or do the right thing? Corporate dilemmas at COP28

Indigenous environmental activist killed in Peru

'I feel safe': the school for environmental defenders

CIVIL NUCLEAR
Net-zero targets must include fossil fuel 'phase-out': monitor

Business as usual: Record number of fossil fuel lobbyists at COP28

Record fossil fuel lobbyists as climate talks face off hardens

No science that oil phase-out will fix climate: COP28 chief

CIVIL NUCLEAR
Farewell, Solar Conjunction 2023: Sols 4023-4024

Was There Life on Mars

NASA Orbiter snaps stunning views of Mars horizon

Perseverance's Parking Spot

Subscribe Free To Our Daily Newsletters




The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.